Yat Sun Or
2018
In 2018, Yat Sun Or earned a total compensation of $1.5M as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 14% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $171,072 |
---|---|
Option Awards | $630,855 |
Salary | $427,950 |
Stock Awards | $275,275 |
Other | $18,851 |
Total | $1,524,003 |
Or received $630.9K in option awards, accounting for 41% of the total pay in 2018.
Or also received $171.1K in non-equity incentive plan, $428K in salary, $275.3K in stock awards and $18.9K in other compensation.
Rankings
In 2018, Yat Sun Or's compensation ranked 7,084th out of 14,244 executives tracked by ExecPay. In other words, Or earned more than 50.3% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 7,084 | 50th |
Manufacturing | 2,722 | 53rd |
Chemicals And Allied Products | 1,024 | 52nd |
Drugs | 863 | 52nd |
Pharmaceutical Preparations | 673 | 51st |
Or's colleagues
We found four more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2018.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019